Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.
about
Validation of anti-aging drugs by treating age-related diseases.An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.Rapamune does not attenuate high cholesterol-induced atherosclerosis in rabbits.Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis.Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connectionPerspectives of Targeting mTORC1-S6K1 in Cardiovascular AgingRapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disordersInterferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.Koschei the immortal and anti-aging drugsSerendipity in splendid isolation: rapamycinDysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?Physiological difference in autophagic flux in macrophages from 2 mouse strains regulates cholesterol ester metabolismManagement of dyslipidemia in patients after solid organ transplantation.Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.Considerations in sirolimus use in the early and late post-transplant periods.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Autophagy--a key player in cellular and body metabolism.Mechanistic perspectives of calorie restriction on vascular homeostasis.Potential therapeutic effects of mTOR inhibition in atherosclerosis.Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System.Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts.Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptorThe use of everolimus in renal-transplant patientsUse of mTOR inhibitors in human organ transplantation.Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice.An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.Rapamycin modulates the eNOS vs. shear stress relationship.Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.The activation of mTOR is required for monocyte pro-inflammatory response in patients with coronary artery disease.Folic acid delays development of atherosclerosis in low-density lipoprotein receptor-deficient mice.Bioactive components and mechanisms of Chinese poplar propolis alleviates oxidized low-density lipoprotein-induced endothelial cells injury.
P2860
Q33588700-EFAA9EE9-E372-43AA-B380-CF2ED9C83A1DQ33827198-AA56957B-AFD7-43DD-97AF-5B6FB0FCDEB9Q33848041-6C534FD4-3989-47A1-86E9-D902A03149A9Q33896755-C1E1F277-1E89-48F2-AEBC-6EBB49E10360Q34213257-755D14FF-CD4A-4FF0-AAAC-34A63CAC15A8Q35693660-D130EDB6-A311-4F90-BDC0-936113B9067CQ35911400-AF4E7098-C720-4833-AC23-EE2DF666D063Q36259538-C8F2E0CC-824C-4CBD-A54A-1AE5ED8535F5Q36292001-2CA68803-BEE1-4C01-9DEF-9EB33D95414FQ36443126-C4C3B469-FC86-415A-A2C2-DBAC10C8291EQ36727852-A6880E39-F4A5-4720-9FC6-697BDA8DE371Q36752124-7C6147D6-63B3-4E8F-9CB7-7531277C98ABQ36822328-10049FB2-297F-44BB-8FE0-7E49A97181BCQ37158327-8131E8C3-B6A8-432D-8588-AA76AE2B28BAQ37176562-EA980980-4F05-41E9-AD46-14821880BC6AQ37517602-8C7C1439-06B4-411F-A00D-C599CF6B2CB9Q37649641-84AFB257-3DF7-46F8-B560-691843239D17Q37873950-834A950B-E996-42BF-BD74-FC8C758157E2Q38198952-316BB345-AADA-4CA5-A0B1-5A00B2A44759Q38238017-5A7D6E0E-BD4A-4F21-AC48-66F102BCC7D8Q38628797-62EAEF05-5F88-44C7-94A7-9217B47DAC37Q38899693-D0120238-7E72-4713-AFBB-EC0E52E1E182Q40446287-526A18DC-EB77-4D61-8B24-8EF9C51BEDADQ41424778-991D2DE6-1A68-4F82-AE90-8A5021B401E5Q41859603-EFBCA61D-A553-469C-A4D5-446DF6EC238DQ43061556-2F384A29-81A6-4476-8D5F-3B10ED1A0393Q43247378-8F490BBA-EF97-41A6-8EA6-D1F448D074E1Q45230221-6B555373-D9E4-4C53-B6C8-6BE6FDD4D727Q46851063-E4924CFD-E8B7-4D01-9C23-4BD077A574E6Q50703978-6F7B4F96-C773-4853-B821-F5E717331A67Q51312253-BFE05898-9CB8-49BE-BF82-34EDFA9B67ACQ52640082-A3728F16-48AE-4EE8-9196-95491EE3303DQ54979811-63ED789F-AD4E-43C9-9C7B-87CFD3DDAC5E
P2860
Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Protective effect of the immun ...... rosis in apo E-deficient mice.
@en
Protective effect of the immun ...... rosis in apo E-deficient mice.
@nl
type
label
Protective effect of the immun ...... rosis in apo E-deficient mice.
@en
Protective effect of the immun ...... rosis in apo E-deficient mice.
@nl
prefLabel
Protective effect of the immun ...... rosis in apo E-deficient mice.
@en
Protective effect of the immun ...... rosis in apo E-deficient mice.
@nl
P2093
P2860
P1476
Protective effect of the immun ...... rosis in apo E-deficient mice.
@en
P2093
Caroline A Kopec
Kristen L Phiel
M Merle Elloso
Michael D Basso
Neal Azrolan
Pa-Lang Hsu
Steven J Adelman
Suren N Sehgal
P2860
P304
P356
10.1034/J.1600-6143.2003.00094.X
P407
P577
2003-05-01T00:00:00Z